According to Rospotrebnadzor (the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing), the results of 2013 demonstrate a decline in TB morbidity rate vs. 2012 on the RF territory: by 8% for the newly diagnosed active TB forms and by 8.1% - for TB of the respiratory system. These indicators are higher than the decline rates in 2011-2012 – 5.8% and 5.5%, respectively. 

Abercade analysts point out that two types of vaccines used for TB prevention are available on the market (BCG and BCG-M). Following the results of 2013, based on the evaluation in physical terms (units) the leading positions are kept by vaccines with reduced antigenic load (BCG-M). As a rule, they are used for TB prevention in newborn infants – 65% of the overall market size. However, in 2005 the share of BCG-M vaccines made up about 20% of the overall market volume expressed in physical terms. Such considerable strengthening of the market positions of BCG-M vaccines is explained by the fact that in 2008 a decision was made to use mostly vaccines with reduced antigenic load for the immunization of newborn infants in view of the increased number of post-vaccination complications from BCG-vaccines.